Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Update Presentation - Genmab's CEO, Jan van de Winkel, will present a company update at the 43rd Annual J P Morgan Healthcare Conference on January 14, 2025, at 3:00 PM PST / 6:00 PM EST [1] - The presentation will be available via live and archived webcast on Genmab's website [1] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve the lives of patients with cancer and other serious diseases [2] - The company has over 25 years of experience in inventing next-generation antibody technology platforms, leveraging translational, quantitative, and data sciences [2] - Genmab's proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function-enhanced antibodies [2] - By 2030, the company aims to transform patient lives with its "knock-your-socks-off" (KYSO) antibody medicines [2] - Genmab was established in 1999 and is headquartered in Copenhagen, Denmark, with a global presence across North America, Europe, and Asia Pacific [2] Trademarks and Legal Information - Genmab and its subsidiaries own several trademarks, including Genmab, the Y-shaped Genmab logo, HuMax, DuoBody, HexaBody, DuoHexaBody, HexElect, and KYSO [4]